Close Menu

NEW YORK – The Blood Profiling Atlas in Cancer Consortium (BloodPAC) has released a series of analytical protocols for validating next-generation sequencing (NGS)-based circulating tumor DNA (ctDNA) assays, which the consortium believes will help accelerate the development and regulatory reviews of new tests.

Developed by consortium members, the resource may potentially serve as a set of generic analytical protocols and help to define industry standards for developing liquid biopsy assays.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Lancet has made changes to its peer-review process in response to its recent retraction of a COVID-19-related paper, Science reports.

The New York Times reports that a series of emails show how Department of Health and Human Services officials sought to silence the Centers for Disease Control and Prevention.

A new initiative aims to move Australia's genome sequencing labs onto one system, the Sydney Morning Herald reports.

In PLOS this week: recessive mutation tied to early-onset dilated cardiomyopathy, epigenetic analysis of lung adenocarcinoma, and more.